Novartis India Ltd vs Titan Biotech Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Novartis India Ltd is ₹ 1050 as of 06 May 15:30 . The P/E Ratio of Novartis India Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Titan Biotech Ltd changed from 5.1 on March 2021 to 16.2 on March 2025 . This represents a CAGR of 26.01% over 5 years The Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Titan Biotech Ltd changed from ₹ 153.33 crore on March 2021 to ₹ 348.36 crore on March 2025 . This represents a CAGR of 17.84% over 5 years The revenue of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Titan Biotech Ltd for the Dec '25 is ₹ 57.76 crore as compare to the Sep '25 revenue of ₹ 55.68 crore. This represent the growth of 3.74% The ebitda of Novartis India Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Titan Biotech Ltd for the Dec '25 is ₹ 12.09 crore as compare to the Sep '25 ebitda of ₹ 10.65 crore. This represent the growth of 13.52% The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Titan Biotech Ltd changed from ₹ 5.7 crore to ₹ 7.87 crore over 7 quarters. This represents a CAGR of 20.24% The Dividend Payout of Novartis India Ltd changed from 118.09 % on March 2021 to 61.15 % on March 2025 . This represents a CAGR of -12.33% over 5 yearsThe Dividend Payout of Titan Biotech Ltd changed from 4.31 % on March 2021 to 9.04 % on March 2025 . This represents a CAGR of 15.97% over 5 years .

About Novartis India Ltd

Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Titan Biotech Ltd

Titan Biotech Limited, the New Delhi based company is into manufacture of Biological Peptones, Extracts and Dehydrated Culture media which are very conducive for the growth of micro organisms.
They are primarily used in the development and growth of micro organisms in clinical diagnosis production of vaccines antibiotics antisera etc, Checking the sensitivity of antibiotics in pharmaceutical industry, checking the bacterial contamination in food & water, tissue culture laboratories and in the departments of microbiology & botony in medical colleges/universities. The company uses Meat, Bile, Pancreatic, Liver, Blood, Brain, Heart and other parts of animals sourced from slaughter house and other vegetable products like soya, casein etc. converting them into free flowing powder to produce Peptones, Extracts and Hydrolysates which are further used in manufacturing of Dehydrated Culture Media and as raw material in pharma health products and other industries.

FAQs for the comparison of Novartis India Ltd and Titan Biotech Ltd

Which company has a larger market capitalization, Novartis India Ltd or Titan Biotech Ltd?

Market cap of Novartis India Ltd is 2,594 Cr while Market cap of Titan Biotech Ltd is 1,949 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Titan Biotech Ltd?

The stock performance of Novartis India Ltd and Titan Biotech Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Titan Biotech Ltd?

As of May 6, 2026, the Novartis India Ltd stock price is INR ₹1050.7. On the other hand, Titan Biotech Ltd stock price is INR ₹471.85.

How do dividend payouts of Novartis India Ltd and Titan Biotech Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Titan Biotech Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.